<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859036</url>
  </required_header>
  <id_info>
    <org_study_id>2014/39</org_study_id>
    <nct_id>NCT04859036</nct_id>
  </id_info>
  <brief_title>The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters</brief_title>
  <official_title>The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kayseri City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kayseri City Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study; we evaluated the heart rate variability parameters of pediatric patients whose&#xD;
      VSDs were closed with the transcatheter method before and after, and compared with the&#xD;
      control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart rate variability (HRV) is a sign of cardiac autonomic nervous system. Evaluation of HRV&#xD;
      in pediatric ventricular septal defect (VSD) cases before and after transcatheter closure&#xD;
      will enlighten us in terms of cardiac autonomic control.&#xD;
&#xD;
      Methods: 19 VSD cases treated with transcatheter closure method and 18 healthy children were&#xD;
      enrolled in the study. 24 hours Holter rhythm monitorization was applied to all patients&#xD;
      before closure of VSD and to the control group. In the patient group, Holter rhythm&#xD;
      monitorization was repeated in the third months. HRV parameters were obtained from Cardio&#xD;
      Scan Premier 12® program. Frequency domain (Total power, VLF, LF, HF, LF/HF ratio) and time&#xD;
      domain analysis (SDNN, SDANN, SDNNi, pNN50, rMSSD) were applied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">April 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate variability parameters</measure>
    <time_frame>24 hours</time_frame>
    <description>Time Domain analysis:&#xD;
After ectopic beats and artifacts were excluded, the following indices were calculated for time domian analysis in the whole Holter recording.&#xD;
SDNN: Standard deviation of all filtered RR intervals&#xD;
SDANN: Standard deviation of 5-minute averages of RR intervals&#xD;
SDNNindex: Mean of the standard deviation of all RR intervals for all the 5-minute segments&#xD;
rMSSD: Square root of the mean of the sum of square differences between adjacent filtered RR interval&#xD;
PNN50: Percentage of the difference between adjacent RR intervals greater than 50 milliseconds&#xD;
Frequency domain analysis:&#xD;
We determined spectral power over three frequency.&#xD;
Very low frequency (VLF) index (0.003-0.04 Hz)&#xD;
Low frequency (LF) index (0.04 - 0.15 Hz)&#xD;
High frequency (HF) index (0.15 - 0.40 Hz)&#xD;
Total power: Variance of all NN intervals approximately &lt;0.4 Hz</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">37</enrollment>
  <condition>Ventricular Septal Defect</condition>
  <condition>Closure; Interventricular Septum</condition>
  <condition>Autonomic Nervous System Imbalance</condition>
  <arm_group>
    <arm_group_label>Transchateter VSD closure group</arm_group_label>
    <description>VSD cases treated with transcatheter closure method.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healty children</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>24 hours ambulatory Holter monitoring</intervention_name>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Transchateter VSD closure group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient group consists of pediatric patients who underwent transcatheter VSD closure in&#xD;
        our institute.&#xD;
&#xD;
        The control group consists of children who admitted to our institute with the complaint of&#xD;
        palpitations and had a normal Holter record.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  VSD diameter &lt;6mm&#xD;
&#xD;
          -  Significant left-to-right shunt&#xD;
&#xD;
          -  Left atrial and ventricular enlargement detected by echocardiography or calculation of&#xD;
             Qp/Qs ratio above 1.5 in the catheterization laboratory (Qp/Qs&gt;1.5)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with arrhythmia after the procedure&#xD;
&#xD;
          -  Young patients who may be inconsistent during Holter records&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Months</minimum_age>
    <maximum_age>136 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazım Uzum, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>TC Erciyes University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Süleyman Sunkak</name>
      <address>
        <city>Kayseri</city>
        <state>Kocasinan</state>
        <zip>38080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/29541816/</url>
    <description>VSD closure indications</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/8598068/</url>
    <description>Standarts of heart rate variability parameters</description>
  </link>
  <reference>
    <citation>Narin N, Pamukcu O, Tuncay A, Baykan A, Sunkak S, Tasci O, Uzum K, Saltık L. Percutaneous Ventricular Septal Defect Closure in Patients Under 1 Year of Age. Pediatr Cardiol. 2018 Jun;39(5):1009-1015. doi: 10.1007/s00246-018-1852-5. Epub 2018 Mar 15.</citation>
    <PMID>29541816</PMID>
  </reference>
  <reference>
    <citation>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65.</citation>
    <PMID>8598068</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kayseri City Hospital</investigator_affiliation>
    <investigator_full_name>süleyman sunkak</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ventricular septal defect</keyword>
  <keyword>heart rate variability</keyword>
  <keyword>percutaneous VSD closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

